Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) 3-Year Book Growth Rate : 14.40% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Yichang HEC ChangJiang Pharmaceutical Co 3-Year Book Growth Rate?

Yichang HEC ChangJiang Pharmaceutical Co's Book Value per Share for the quarter that ended in Dec. 2023 was HK$9.86.

During the past 12 months, Yichang HEC ChangJiang Pharmaceutical Co's average Book Value per Share Growth Rate was 32.10% per year. During the past 3 years, the average Book Value per Share Growth Rate was 14.40% per year. During the past 5 years, the average Book Value per Share Growth Rate was 16.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 10 years, the highest 3-Year average Book Value per Share Growth Rate of Yichang HEC ChangJiang Pharmaceutical Co was 112.20% per year. The lowest was 11.00% per year. And the median was 21.40% per year.

Competitive Comparison of Yichang HEC ChangJiang Pharmaceutical Co's 3-Year Book Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Yichang HEC ChangJiang Pharmaceutical Co's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yichang HEC ChangJiang Pharmaceutical Co's 3-Year Book Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Yichang HEC ChangJiang Pharmaceutical Co's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where Yichang HEC ChangJiang Pharmaceutical Co's 3-Year Book Growth Rate falls into.

Yichang HEC ChangJiang Pharmaceutical Co 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

Yichang HEC ChangJiang Pharmaceutical Co 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of Yichang HEC ChangJiang Pharmaceutical Co's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Yichang HEC ChangJiang Pharmaceutical Co Ltd (HKSE:01558) » Definitions » 3-Year Book Growth Rate

Traded in Other Exchanges

N/A

Address

No. 38 Binjiang Road, Yidu, Hubei Province, Yichang, CHN

Website

http://www.hec-changjiang.com

Yichang HEC ChangJiang Pharmaceutical Co Ltd functions in the Chinese drug industry. As a domestic manufacturing wing of the HEC Group, Yichang employs its therapeutic technology to address viral, endocrine, metabolic, and cardiovascular diseases. The company's key revenue driver is the anti-viral product division, which manufactures its key product, Kewei. It is one of the leading products in China's anti-influenza market. Its other products include Ertongshu, Oumeining, Olmesartan Tablets, and Clarithromycin Tablets.

Yichang HEC ChangJiang Pharmaceutical Co (HKSE:01558) Headlines

No Headlines